€594.30
Your prediction
Regeneron Pharmaceuticals Inc. Stock
Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Pros and Cons of Regeneron Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Regeneron Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 0.150% | 1.523% | 12.068% | 26.041% | -10.525% | -7.281% | 20.049% |
| Incyte Corp. | -0.490% | -1.687% | 18.715% | 71.371% | 21.111% | 85.387% | 53.707% |
| IQVIA Holdings Inc. | 0.000% | 0.601% | 19.242% | 34.934% | -4.687% | -6.574% | -11.811% |
| Vertex Pharmaceuticals Inc. | 0.450% | -2.164% | 8.823% | 5.251% | 8.476% | 35.297% | 147.929% |
Comments
News
2 Underrated Weight Loss Stocks to Buy and Hold
Investors interested in weight-loss stocks may naturally gravitate toward Eli Lilly and Novo Nordisk. That makes sense. They are currently the leaders in this niche. Their brands, Zepbound and
Is This Biotech Stock a Buy After a Groundbreaking Approval?
While some biotech investors are focused on the weight-loss market (and with good reason), breakthroughs are happening elsewhere. Take Regeneron (NASDAQ: REGN), a major player in the industry. The
Is Regeneron a Buy After the FDA Approved its Gene Therapy to Restore Hearing?
Shares of Regeneron Pharmaceuticals (NASDAQ: REGN) are down more than 11% this year, and fell 5% on April 29, a day after the biotech company announced better-than-expected first-quarter earnings.